Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs.
Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs.
复制标题
百日咳和百日咳疫苗。
DOI：
--
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
J. Koplan
中科院分区：
文献类型：
--
作者：
A. Hinman;J. Koplan
利用最近公布的信息，我们对100万名儿童进行了从出生到6岁的随访，这些儿童没有接种百日咳疫苗，也没有接种。没有估计与死亡或工资损失有关的费用。一个覆盖90%儿童的疫苗接种计划将使疾病发病率和与疾病相关的费用降低90%。考虑到与疫苗和疫苗反应相关的成本，成本降低了82%。没有项目的总成本与有项目的总成本之比是5.7:1。收益成本比为11.1:1。因为我们没有包括间接成本，这是一个保守的估计。在改进的疫苗可用之前，继续使用我们现有的疫苗，并仔细注意可能的禁忌症，似乎是唯一谨慎的做法。
Using recently published information, we examined the experience of a hypothetical cohort of 1 million children followed up from birth to 6 years of age without and with a pertussis vaccination program. Costs associated with death or lost wages were not estimated. A vaccination program reaching 90% of children would reduce disease incidence and disease-related costs by 90%. Taking into account costs associated with vaccine and vaccine reactions, the costs are reduced 82%. The ratio of overall costs without a program to those with a program is 5.7:1. The benefit-cost ratio is 11.1:1. Because we did not include indirect costs, this is a conservative estimate. Until improved vaccines are available, continued use of our present vaccines, with careful attention to possible contraindications, seems the only prudent course to follow.